A Phase 1 dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamics of AsiDNA, a first-in-class DNA repair inhibitor, administered intravenously in patients with advanced solid tumours.
Auteurs : Le Tourneau C, Delord JP, Kotecki N, Borcoman E, Gomez-Roca C, Hescot S, Jungels C, Vincent-Salomon A, Cockenpot V, Eberst L, Molé A, Jdey W, Bono F, Trochon-Joseph V, Toussaint H, Zandanel C, Adamiec O, de Beaumont O, Cassier PA Année : 2020 Journal : Br J Cancer
159P The clinical landscape of central nervous system (CNS) involvement in metastatic triple-negative breast cancer (TNBC) patients (pts)
Auteurs : Eiger D, de Azambuja E, Moreau M, Bondele J, Sotiriou C, Franzoi MA, Brandão M, Rediti M, Wang X, Awada A, Kotecki N Année : 2020 Journal : Ann Oncol
Clinical implications of body mass index in metastatic breast cancer patients treated with abemaciclib and endocrine therapy.
Auteurs : Franzoi MA, Eiger D, Ameye L, Ponde N, Caparica R, de Angelis C, Brandão M, Desmedt C, Di Cosimo S, Kotecki N, Lambertini M, Awada A, Piccart-Gebhart M, de Azambuja E Année : 2020 Journal : J Natl Cancer Inst
Targeting molecular subtypes in solid cancers: successes and failures.
Auteurs : Assi R, Kotecki N, Awada A Année : 2020 Journal : Curr Opin Oncol
How to assimilate the tsunami of immune checkpoints inhibitors data into clinical practice?
Auteurs : Castelo-Branco L, Aspeslagh S, Kotecki N, Awada A Année : 2019 Journal : Curr Opin Oncol